ETON vs. SPRY, IRON, VERA, MESO, IMCR, TVTX, INDV, EWTX, OCUL, and CALT
Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include ARS Pharmaceuticals (SPRY), Disc Medicine (IRON), Vera Therapeutics (VERA), Mesoblast (MESO), Immunocore (IMCR), Travere Therapeutics (TVTX), Indivior (INDV), Edgewise Therapeutics (EWTX), Ocular Therapeutix (OCUL), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry.
Eton Pharmaceuticals vs.
Eton Pharmaceuticals (NASDAQ:ETON) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, community ranking, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.
In the previous week, ARS Pharmaceuticals had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 5 mentions for ARS Pharmaceuticals and 4 mentions for Eton Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 1.56 beat Eton Pharmaceuticals' score of 0.54 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.
ARS Pharmaceuticals has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -15.81%. ARS Pharmaceuticals' return on equity of -22.56% beat Eton Pharmaceuticals' return on equity.
Eton Pharmaceuticals has higher earnings, but lower revenue than ARS Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 14.9% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 40.1% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Eton Pharmaceuticals received 73 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 86.21% of users gave ARS Pharmaceuticals an outperform vote while only 65.77% of users gave Eton Pharmaceuticals an outperform vote.
Eton Pharmaceuticals currently has a consensus price target of $27.67, suggesting a potential upside of 96.50%. ARS Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 108.33%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Eton Pharmaceuticals.
Eton Pharmaceuticals has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
Summary
ARS Pharmaceuticals beats Eton Pharmaceuticals on 15 of the 19 factors compared between the two stocks.
Get Eton Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eton Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ETON) was last updated on 4/16/2025 by MarketBeat.com Staff
